- Medical Director, Integrative and Supportive Oncology Program, UH Seidman Cancer Center
- Director, Supportive and Integrative Oncology, UH Cleveland Medical Center
- Interim Director, Palliative Care, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
- Gastrointestinal Cancers
- Integrative Oncology
- Medical Research
- Palliative Medicine
Patient Experience Reviews
4.7 out of 5
Patient Comments (6)
Reviewed On 7/1/2021
Reviewed On 7/1/2021
Professional & empathetic care, A+
Reviewed On 6/1/2021
Dr. Lee is a very caring doctor. His bedside manner exceeds what I expected. He listens and always makes sure I am comfortable and understand everything about my illness. I just want to express my thanks to UH for having Dr. Lee on their staff! I know he will get me through whatever I am facing with this illness. Kudos to you Dr. Lee.
Reviewed On 1/1/2021
very knowledgeable and straight forward.
Reviewed On 12/1/2020
The doctor was extremely negative. ***
Reviewed On 11/1/2020
i appreciate the time dr lee spends answering my questions, i never feel rushed during my visits.
- Hospice and Palliative Medicine - American Board of Internal Medicine
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Fellowship | Hospice and Palliative Medicine
Hospice and Palliative Medicine - Mcgaw Medical Center Of Northwestern University (2008 - 2009)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Of Chicago Medical Center (2005 - 2008)
Fellowship | Acupuncture
Acupuncture - China Medical University Hospital (2004 - 2005)
Residency | Internal Medicine
Internal Medicine - Stanford Hospital And Clinics (2001 - 2004)
George Washington University School Of Medicine And Health Sciences (2001)
George Washington University (1998)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Richard Lee did not disclose any Outside Relationships with Industry.